Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6218MR)

This product GTTS-WQ6218MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6218MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12985MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ15564MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ15558MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ15599MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ6235MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ11364MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ15134MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ4823MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW